The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
GIVLAARI (Alnylam Australia Pty Ltd)
Product name
GIVLAARI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
157 (175 working days)
Active ingredients
givosiran sodium
Registration type
NCE/NBE
Indication
Givlaari is indicated for the treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older.